First author Study Name N Study Design F-up Results Cooper [25 ] STEAL 350 Randomized to switch from current NRTI to
or
FDC in HLA-B
adults with plasma HIV viral load
50
. 96 w No significant difference for insulin sensitivity, total cholesterol (TC):HDL cholesterol (HDL-C) ratio, or lactate. Martinez [26 ] BICOMBO 335 Randomized to switch from 3TC-containing triple regimens to
or
FDC
in patients with
200
for at least 6 months 48 w One case of AMI Sax [27 ] ACTG 5202 1858 Naïve patients randomized to 4 once-daily antiretroviral regimens: ABC+3TC or TDF+FTC plus efavirenz or ritonavir-boosted atazanavir. 96 w ABC+3TC versus TDF+FTC median change in TC: 34 versus 26 mg/dL,
; HDL-C: 9 versus 7 mg/dL,
; triglyceride (TG): 25 versus 3 mg/dL,
. Wamsley [28 ] GEMINI 337 Naïve patients randomized to either SQV/r 1000 mg/100 mg twice a day (167) or LPV/r 400 mg/100 mg twice a day (170), plus
48 w No significant differences in the median change from baseline between arms in plasma lipids except for TG, significantly higher in the LPV/r arm Eron [29 ] KLEAN 878 Naïve patients randomized to either fosamprenavir-ritonavir 700 mg/100 mg twice daily or lopinavir-ritonavir 400 mg/100 mg twice daily, plus ABC/3TC 48 w No significant differences between arms. Molina [30 ] CASTLE 883 Naïve patients randomized to atazanavir/ritonavir 300/100 mg once daily (440) opinavir/ritonavir 400/100 mg twice daily (443) plus
24 m Mean changes from baseline in TC, LDL-C, and TG were significantly higher with lopinavir/ritonavir
. Mills [31 ] ARTEMIS 689 Naïve patients with HIV-1 RNA at least 5000 copies/ml (stratified by HIV-1 RNA and CD4 cell count) randomized to DRV/r 800/100 mg once daily or LPV/r 800/200 mg total daily dose (twice daily or once daily) plus
96 w DRV/r patients had smaller median increases in TG (0.1 and 0.6 mmol/L, resp.,
) and TC (0.6 and 0.9 mmol/L, resp.,
) than LPV/r patients
